|
Synonyms: REGN475 | SAR164877
Compound class:
Antibody
Comment: Fasinumab is an investigational, fully human IgG4κ monoclonal antibody targeting nerve growth factor (NGF).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical matches to peptide sequences submitted with patent US7988967 [4], with the preferred antibody being called REGN475 therein. REGN475 exhibits high specificity for human NGF, does not cross-react with closely related neurotrophin-3 (NT-3) and inhibits binding of NGF to its receptors TrkA (NTRK1) and p75 (NGFR) [4]. |
| No information available. |
Summary of Clinical Use  |
| Fasinumab is being evaluated as a monotherapy in Phase 3 clinical trial (NCT02620020) for its potential to treat chronic low back pain. |
| Mechanism Of Action and Pharmacodynamic Effects |
| An extensive body of evidence indicates a pivotal contribution of NGF to pain mechanisms in the adult mammalian nervous system, with elevated levels of NGF reported in several painful conditions in humans [1-2]. Fasinumab specifically neutralizes the biological actions of human NGF, and this is expected to produce clinical pain relief [3]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02620020 | A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain | Phase 2/Phase 3 Interventional | Regeneron Pharmaceuticals | ||
